Total Payments
$163,669
2024 Payments
$343.72
Companies
31
Transactions
279
Medicare Patients
7,335
Medicare Billing
$930,155
Payment Breakdown by Category
Research$160,408 (98.0%)
Food & Beverage$3,240 (2.0%)
Education$21.62 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $160,408 | 15 | 98.0% |
| Food and Beverage | $3,240 | 262 | 2.0% |
| Education | $21.62 | 2 | 0.0% |
Payments by Type
Research
$160,408
15 transactions
General
$3,262
264 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Celltrion, Inc. | $137,775 | 5 | $0 (2023) |
| Eli Lilly and Company | $22,633 | 10 | $0 (2023) |
| ABBVIE INC. | $979.23 | 75 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $487.11 | 37 | $0 (2024) |
| Janssen Biotech, Inc. | $447.70 | 47 | $0 (2022) |
| PFIZER INC. | $209.61 | 27 | $0 (2022) |
| Allergan Inc. | $146.99 | 22 | $0 (2019) |
| Merz North America, Inc. | $126.88 | 2 | $0 (2023) |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $97.37 | 6 | $0 (2024) |
| Celgene Corporation | $93.85 | 5 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $343.72 | 19 | ABBVIE INC. ($109.40) |
| 2023 | $48,381 | 20 | Celltrion, Inc. ($45,752) |
| 2022 | $57,289 | 22 | Celltrion, Inc. ($57,021) |
| 2021 | $18,339 | 15 | Eli Lilly and Company ($17,157) |
| 2020 | $20,330 | 14 | Celltrion, Inc. ($20,088) |
| 2019 | $15,297 | 42 | Celltrion, Inc. ($13,915) |
| 2018 | $3,240 | 109 | Eli Lilly and Company ($2,186) |
| 2017 | $449.79 | 38 | AbbVie, Inc. ($235.65) |
All Payment Transactions
279 individual payment records from CMS Open Payments — Page 1 of 12
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/20/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $20.70 | General |
| Category: Gastroenterology | ||||||
| 11/19/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $26.64 | General |
| Category: Gastroenterology | ||||||
| 11/19/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $13.72 | General |
| Category: IMMUNOLOGY | ||||||
| 11/18/2024 | Antares Pharma, Inc. | XYOSTED (Drug) | Food and Beverage | In-kind items and services | $18.19 | General |
| Category: TESTOSTERONE REPLACEMENT THERAPY | ||||||
| 10/14/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $14.81 | General |
| Category: IMMUNOLOGY | ||||||
| 10/02/2024 | Takeda Pharmaceuticals U.S.A., Inc. | EOHILIA (Drug) | Education | In-kind items and services | $13.76 | General |
| Category: INTERNAL MEDICINE | ||||||
| 09/26/2024 | Madrigal Pharmaceuticals | RESMETIROM (Drug) | Food and Beverage | In-kind items and services | $19.45 | General |
| Category: LIVER DISEASE | ||||||
| 09/20/2024 | CapsoVision, Inc. | CapsoCam Plus (Device) | Food and Beverage | Cash or cash equivalent | $18.22 | General |
| Category: Gastroenterology | ||||||
| 09/16/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $14.73 | General |
| Category: IMMUNOLOGY | ||||||
| 07/30/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $13.74 | General |
| Category: IMMUNOLOGY | ||||||
| 04/05/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $23.28 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 03/21/2024 | ABBVIE INC. | CREON (Drug) | Food and Beverage | In-kind items and services | $24.25 | General |
| Category: ENDOCRINOLOGY | ||||||
| 03/16/2024 | Ipsen Biopharmaceuticals, Inc | Bylvay (Drug) | Food and Beverage | In-kind items and services | $17.90 | General |
| Category: Gastroenterology | ||||||
| 02/23/2024 | Daiichi Sankyo Inc. | INJECTAFER (Drug) | Food and Beverage | In-kind items and services | $20.76 | General |
| Category: Iron Deficiency Anemia | ||||||
| 02/16/2024 | Intercept Pharmaceuticals, Inc. | OCALIVA (Drug) | Food and Beverage | In-kind items and services | $17.02 | General |
| Category: Hepatology / Gastroenterology | ||||||
| 02/15/2024 | Ipsen Biopharmaceuticals, Inc | Bylvay (Drug) | Food and Beverage | In-kind items and services | $19.22 | General |
| Category: Gastroenterology | ||||||
| 02/14/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $19.18 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 02/03/2024 | ABBVIE INC. | LINZESS (Drug), CREON | Food and Beverage | In-kind items and services | $13.23 | General |
| Category: GASTROENTEROLOGY | ||||||
| 01/24/2024 | ABBVIE INC. | LINZESS (Drug), VIBERZI, CREON | Food and Beverage | In-kind items and services | $14.92 | General |
| Category: GASTROENTEROLOGY | ||||||
| 12/11/2023 | AbbVie Inc. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $9.87 | General |
| Category: IMMUNOLOGY | ||||||
| 11/02/2023 | AbbVie Inc. | LINZESS (Drug) | Food and Beverage | In-kind items and services | $8.72 | General |
| Category: GASTROENTEROLOGY | ||||||
| 10/25/2023 | AbbVie Inc. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $9.31 | General |
| Category: IMMUNOLOGY | ||||||
| 10/16/2023 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $19.94 | General |
| Category: Neuroscience | ||||||
| 10/11/2023 | Merz North America, Inc. | Xeomin (Biological) | Food and Beverage | In-kind items and services | $36.88 | General |
| Category: Musculoskeletal | ||||||
| 10/10/2023 | Merz North America, Inc. | Xeomin (Biological) | Food and Beverage | In-kind items and services | $90.00 | General |
| Category: Dermatology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| CT-P13 3.8 | Celltrion, Inc. | $117,687 | 4 |
| CT-P13 3.7, CT-P13 3.8 | Celltrion, Inc. | $20,088 | 1 |
| A PHASE 3B, RANDOMIZED, DOUBLE-BLIND, PARALLEL-ARM, PLACEBO- AND ACTIVE- CONTROLLED TREAT-THROUGH STUDY OF MIRIKIZUMAB AND VEDOLIZUMAB IN PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS | Eli Lilly and Company | $9,600 | 1 |
| A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL, PLACEBO-CONTROLLED INDUCTION STUDY OF MIRIKIZUMAB IN CONVENTIONAL-FAILED AND BIOLOGIC-FAILED PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (LUCENT 1) | Eli Lilly and Company | $5,329 | 3 |
| A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-ARM, PLACEBO-CONTROLLED MAINTENANCE STUDY OF MIRIKIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (LUCENT 2) | Eli Lilly and Company | $5,188 | 4 |
| A MULTICENTER PHASE 3B OPEN-LABEL SINGLE-ARM STUDY TO INVESTIGATE BOWEL URGENCY AND ITS RELATIONSHIP WITH OTHER OUTCOME MEASURES IN ADULTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS TREATED WITH MIRIKIZUMAB | Eli Lilly and Company | $2,250 | 1 |
| A PHASE 3, MULTICENTER, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG TERM EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS LUCENT 3 | Eli Lilly and Company | $265.78 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 19 | 1,274 | 1,413 | $1.1M | $175,373 |
| 2022 | 22 | 1,601 | 1,795 | $1.2M | $208,402 |
| 2021 | 24 | 2,165 | 2,496 | $1.5M | $276,435 |
| 2020 | 25 | 2,295 | 2,793 | $1.4M | $269,945 |
Total Patients
7,335
Total Services
8,497
Medicare Billing
$930,155
Procedure Codes
111
All Medicare Procedures & Services
111 procedure records from CMS Medicare Utilization — Page 1 of 5
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 43249 | Balloon dilation of esophagus, stomach, and/or upper small bowel using a flexible endoscope, less than 3.0 cm | Office | 2023 | 45 | 53 | $111,300 | $40,817 | 36.7% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2023 | 77 | 77 | $112,669 | $15,365 | 13.6% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Office | 2023 | 82 | 91 | $86,450 | $14,376 | 16.6% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Office | 2023 | 43 | 43 | $51,600 | $13,068 | 25.3% |
| 43249 | Balloon dilation of esophagus, stomach, and/or upper small bowel using a flexible endoscope, less than 3.0 cm | Facility | 2023 | 97 | 119 | $247,996 | $12,965 | 5.2% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2023 | 101 | 101 | $123,784 | $12,787 | 10.3% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 179 | 190 | $185,695 | $9,817 | 5.3% |
| 91120 | Test for tone and sensation of rectum and anus | Office | 2023 | 26 | 26 | $20,150 | $9,318 | 46.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 82 | 94 | $21,444 | $8,485 | 39.6% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Office | 2023 | 20 | 21 | $31,500 | $7,594 | 24.1% |
| 91122 | Study of rectum sensitivity and function | Office | 2023 | 26 | 26 | $11,700 | $5,419 | 46.3% |
| G0121 | Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | Office | 2023 | 14 | 14 | $11,200 | $4,101 | 36.6% |
| G0121 | Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | Facility | 2023 | 18 | 18 | $14,845 | $3,234 | 21.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 22 | 22 | $9,323 | $2,550 | 27.4% |
| G0105 | Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 2023 | 14 | 14 | $11,644 | $2,508 | 21.5% |
| 43236 | Injection of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 13 | 38 | $34,200 | $2,207 | 6.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 31 | 32 | $5,278 | $1,794 | 34.0% |
| 45378 | Diagnostic exam of large bowel using a flexible endoscope | Facility | 2023 | 13 | 13 | $11,738 | $1,706 | 14.5% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 44 | 46 | $2,864 | $1,597 | 55.8% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 24 | 24 | $7,270 | $1,490 | 20.5% |
| 97166 | Evaluation for occupational therapy, typically 45 minutes | Office | 2023 | 16 | 16 | $3,131 | $1,139 | 36.4% |
| G0500 | Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | Facility | 2023 | 233 | 277 | $20,775 | $1,128 | 5.4% |
| 97165 | Evaluation for occupational therapy, typically 30 minutes | Office | 2023 | 14 | 14 | $2,100 | $1,017 | 48.4% |
| 91200 | Measurement of liver stiffness | Office | 2023 | 40 | 44 | $3,300 | $891.76 | 27.0% |
| 43249 | Balloon dilation of esophagus, stomach, and/or upper small bowel using a flexible endoscope, less than 3.0 cm | Office | 2022 | 35 | 48 | $100,800 | $40,730 | 40.4% |
About Dr. Allan Coates, DO
Dr. Allan Coates, DO is a Gastroenterology healthcare provider based in Wyoming, Michigan. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/01/2006. The National Provider Identifier (NPI) number assigned to this provider is 1972510378.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Allan Coates, DO has received a total of $163,669 in payments from pharmaceutical and medical device companies, with $343.72 received in 2024. These payments were reported across 279 transactions from 31 companies. The most common payment nature is "" ($160,408).
As a Medicare-enrolled provider, Coates has provided services to 7,335 Medicare beneficiaries, totaling 8,497 services with total Medicare billing of $930,155. Data is available for 4 years (2020–2023), covering 111 distinct procedure/service records.
Ad
Practice Information
- Specialty Gastroenterology
- Other Specialties Gastroenterology
- Location Wyoming, MI
- Active Since 08/01/2006
- Last Updated 10/31/2025
- Taxonomy Code 207RG0100X
- Entity Type Individual
- NPI Number 1972510378
Products in Payments
- STELARA (Biological) $433.79
- Amitiza (Drug) $280.25
- Creon (Drug) $241.77
- RINVOQ (Biological) $174.80
- XELJANZ (Drug) $158.88
- Humira (Biological) $155.46
- LINZESS (Drug) $149.99
- Xeomin (Biological) $126.88
- Entyvio (Biological) $102.98
- XIFAXAN (Drug) $97.37
- MAVYRET (Drug) $95.82
- ZEPOSIA (Drug) $93.85
- ENTYVIO (Biological) $88.15
- CREON (Drug) $87.24
- HUMIRA (Biological) $83.93
- Cimzia (Drug) $62.47
- ZENPEP (Drug) $55.93
- Mavyret (Drug) $49.92
- DUPIXENT (Biological) $42.46
- INJECTAFER (Drug) $37.15
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Gastroenterology Doctors in Wyoming
John Serini, Do, DO
Gastroenterology — Payments: $2,860
Gastroenterology $2,860
Thomas Riley, Md, MD
Gastroenterology — Payments: $2,010
Gastroenterology $2,010
Dr. Ryan Hamby, Do, DO
Gastroenterology — Payments: $1,846
Gastroenterology $1,846
Dr. Luke Deroo, D.o, D.O
Gastroenterology — Payments: $687.34
Gastroenterology $687.34
Dr. Armita Ghoddousi, Do, DO
Gastroenterology — Payments: $634.01
Gastroenterology $634.01
Gregory Cammell, Md, MD
Gastroenterology
Gastroenterology